Pembrolizumab news

All news on Pembrolizumab (also known as KEYTRUDA): plants, production capacities, investments and involved companies in Europe.

19 September 2025
FDA Approves Merck's Subcutaneous KEYTRUDA QLEX for Solid Tumors
KEYTRUDA QLEX, a subcutaneous immune checkpoint inhibitor, offers comparable efficacy to IV KEYTRUDA in treating metastatic NSCLC, with administration possible in one minute by healthcare providers.

Who will be producing Pembrolizumab in the future?

Find out with chemXplore Analytics